mitochondrial ribosomal protein L42 pseudogene 4Genealiases: []
Q-omics provides the consensus-scored MRPL42P4 profile across patient tissues and cancer cell-line models. MRPL42P4 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MRPL42P4 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, MRPL42P4 RNA expression shows 7,163 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRP, KIRC, and LIHC as cancer lineages where MRPL42P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL42P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL42P4 survival associations across molecular data types. MRPL42P4 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL42P4 RNA expression–survival associations across cancer types. High MRPL42P4 expression shows unfavorable associations in KIRP, BRCA, UCEC, READ, DLBC and STAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MRPL42P4 RNA expression.
This table summarizes MRPL42P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MRPL42P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL42P4 shows lower tumor expression in KIRC and higher tumor expression in STAD and HNSC. The KIRC box plot shows higher MRPL42P4 RNA expression in normal versus tumor tissue (log2 FC = −0.031, t-test p = .011).
This table shows molecular features associated with MRPL42P4 in patient tissues and cancer cell lines. In patient samples, MRPL42P4 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
